A phase I, single center, randomized, double-blind, placebo controlled, single dose (SD) and multiple dose (MD), dose-escalation clinical trial to evaluate the tolerability and preliminary antiviral activity of therapeutic hepatitis B adenovirus injection (T101) in chronic hepatitis B patients.
Phase of Trial: Phase I
Latest Information Update: 10 Jul 2018
At a glance
- Drugs T 101 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Transgene Tasly (Tianjin) BioPharmaceutical
- 10 Jul 2018 According to a Transgene media release, Tasly Biopharmaceuticals will control all research, development and commercial rights to T101 in Greater China.
- 26 Apr 2018 According to a Transgene media release, first patient has been treated in China in this trial.
- 21 Mar 2018 According to a Transgene media release, full results are expected in 2H 2018.